---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002522"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:48:51.491929+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance

## Summary
- Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.
- Company has 180 days, until July 7, 2025, to regain compliance by having closing bid price ≥$1.00 for 10 consecutive business days.
- If compliance not achieved, may transfer to Nasdaq Capital Market for additional 180-day period, subject to meeting other listing standards.
- Company intends to monitor bid price and consider options including potential reverse stock split if needed.

## SEC filing metadata
- accession: 0001104659-25-002522
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/0001104659-25-002522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/tm252702d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002522
- JSON: https://secwatch.observer/filing/0001104659-25-002522.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002522.txt

## Key facts
- Listing & Compliance Notices
  Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/0001104659-25-002522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.